[1] ZHOU F, ZHOU J, WANG W, et al.Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018:a systematic review and Meta-analysis[J].Hepatology, 2019, 70:1119-1133.
[2] YOUNOSSI Z, TACKE F, ARRESE M, et al.Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J].Hepatology, 2019, 69(6):2672-2682.
[3] ANSTEE Q M, REEVES H L, KOTSILITI E, et al.From NASH to HCC:current concepts and future challenges[J].Nat Rev Gastroenterol Hepatol, 2019, 16:411-428.
[4] PARTHASARATHY G, REVELO X, MALHI H.Pathogenesis of nonalcoholic steatohepatitis:an overview[J].Hepatol Commun, 2020, 4(4):478-492.
[5] YOUNOSSI Z, RINELLA M, SANYAL A, et al.From NAFLD to MAFLD:implications of a premature change in terminology[J].Hepatology, 2021, 73:1194-1198.
[6] 范建高.中国非酒精性脂肪性肝病诊疗指南(2010年修订版)[J].中国医学前沿杂志(电子版), 2012, 4(7):4-10.
[7] 中国高血压防治指南修订委员会.2004年中国高血压防治指南(实用本)[J].诞辰杂志, 2004, 12(23):483-486.
[8] LONARDO A, NASCIMBENI F, MANTOVANI A, et al.Hypertension, diabetes, atherosclerosis and NASH:cause or consequence?[J].J Hepatol, 2018, 68(2):335-352.
[9] 赵天慧, 魏强, 刘茜.非酒精性脂肪肝患者的受控衰减参数与脂代谢异常及颈动脉粥样硬化的关系[J].东南大学学报(医学版), 2020, 39(6):4.
[10] SHEKA A C, ADEYI O, THOMPSON J, et al.Nonalcoholic steatohepatitis:a review[J].JAMA, 2020, 323(12):1175-1183.
[11] ZHAO Y, ZHAO G, CHEN Z, et al.Nonalcoholic fatty liver disease:an emerging driver of hypertension[J].Hypertension, 2020, 75:275-284.
[12] ZHANG T, ZHANG C, ZHANG Y, et al.Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population:a prospective cohort study[J].Atherosclerosis, 2015, 240(1):144-148.
[13] ANENI E C, ONI E T, MARTIN S S, et al.Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk[J].J Hypertens, 2015, 33(6):1207-1214.
[14] GAWRIEH S, WILSON L A, CUMMINGS O W, et al.Histologic findings of advanced fibrosis and cirrhosis in patients with nonalcoholic fatty liver disease who have normal aminotransferase levels[J].Am J Gastroenterol, 2019, 114(10):1626-1635.
[15] JOHNSTON M P, PATEL J, BYRNE C D.Multi-drug approaches to NASH:what's in the development pipeline?[J].Expert Opin Investig Drugs, 2020, 29(2):143-150.
[16] SORRENTINO P, TERRACCIANO L, D'ANGELO S, et al.Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension[J].Am J Gastroenterol, 2010, 105(2):336-344.
[17] PITISUTTITHUM P, CHAN W K, PIYACHATURAWAT P, et al.Predictors of advanced fibrosis in elderly patients with biopsy-confirmed nonalcoholic fatty liver disease:the GOASIA study[J].BMC Gastroenterol, 2020, 20(1):88.
[18] LABENZ C, HUBER Y, KALLIGA E, et al.Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany[J].Aliment Pharmacol Ther, 2018, 48(10):1109-1116.
[19] KANWAL F, KRAMER J R, LI L, et al.Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease[J].Hepatology, 2020, 71(3):808-819.
[20] 黎娜.体重指数和腰高比联合评估非酒精性脂肪性肝病发病风险的研究[D].大连:大连医科大学, 2021. |